• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

麦角酰二乙胺的卷土重来。第六部分:1-环丙甲酰基-D-麦角酸二乙酰胺(1CP-LSD)的分析和行为特征。

Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).

机构信息

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.

Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St James Hospital, Dublin, Ireland.

出版信息

Drug Test Anal. 2020 Jun;12(6):812-826. doi: 10.1002/dta.2789. Epub 2020 Apr 20.

DOI:10.1002/dta.2789
PMID:32180350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9191646/
Abstract

Lysergic acid diethylamide (LSD) is a prototypical serotonergic psychedelic drug and the subject of many clinical investigations. In recent years, a range of lysergamides has emerged with the production of some being inspired by the existing scientific literature. Others, for example various 1-acyl substituted lysergamides, did not exist before their appearance as research chemicals. 1-Cylopropanoyl-LSD (1CP-LSD) has recently emerged as a new addition to the group of lysergamide-based designer drugs and is believed to be psychoactive in humans. In this investigation, 1CP-LSD was subjected to detailed analytical characterizations including various mass spectrometry (MS) platforms, gas and liquid chromatography, nuclear magnetic resonance spectroscopy, solid phase and GC condensed phase infrared spectroscopy. Analysis by GC-MS also revealed the detection of artificially induced degradation products. Incubation of 1CP-LSD with human serum led to the formation of LSD, indicating that it may act as a prodrug for LSD in vivo, similar to other 1-acyl substituted lysergamides. The analysis of blotters and pellets is also included. 1CP-LSD also induces the head-twitch response (HTR) in C57BL/6 J mice, indicating that it produces an LSD-like behavioural profile. 1CP-LSD induced the HTR with an ED = 430.0 nmol/kg which was comparable to 1P-LSD (ED = 349.6 nmol/kg) investigated previously. Clinical studies are required to determine the potency and profile of the effects produced by 1CP-LSD in humans.

摘要

麦角酸二乙酰胺(LSD)是一种典型的血清素致幻药物,也是许多临床研究的主题。近年来,一系列的麦角酰二胺类药物已经出现,其中一些的产生灵感来自现有的科学文献。其他的,例如各种 1-酰基取代的麦角酰二胺类药物,在作为研究化学品出现之前并不存在。1-丙酰基-LSD(1CP-LSD)最近作为一种新型的麦角酰二胺类设计药物出现,被认为对人类具有致幻作用。在这项研究中,1CP-LSD 进行了详细的分析鉴定,包括各种质谱(MS)平台、气相和液相色谱、核磁共振波谱、固相和 GC 凝聚相红外光谱。GC-MS 分析还揭示了检测到的人工诱导降解产物。将 1CP-LSD 与人血清孵育会导致 LSD 的形成,这表明它可能在体内作为 LSD 的前体药物起作用,类似于其他 1-酰基取代的麦角酰二胺类药物。还包括对 blotter 和 pellets 的分析。1CP-LSD 也会在 C57BL/6 J 小鼠中引起头部抽搐反应(HTR),表明它产生了类似于 LSD 的行为特征。1CP-LSD 诱导 HTR 的 ED = 430.0 nmol/kg,与之前研究的 1P-LSD(ED = 349.6 nmol/kg)相当。需要进行临床研究来确定 1CP-LSD 在人类中产生的效力和作用特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/da9327b9e737/nihms-1802271-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/06aa6e79536a/nihms-1802271-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/8510fa0294ef/nihms-1802271-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/747eb38758d2/nihms-1802271-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/ed6ec4f20914/nihms-1802271-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/ddb314ca3013/nihms-1802271-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/b516b2e4c638/nihms-1802271-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/da9327b9e737/nihms-1802271-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/06aa6e79536a/nihms-1802271-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/8510fa0294ef/nihms-1802271-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/747eb38758d2/nihms-1802271-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/ed6ec4f20914/nihms-1802271-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/ddb314ca3013/nihms-1802271-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/b516b2e4c638/nihms-1802271-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c1/9191646/da9327b9e737/nihms-1802271-f0009.jpg

相似文献

1
Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).麦角酰二乙胺的卷土重来。第六部分:1-环丙甲酰基-D-麦角酸二乙酰胺(1CP-LSD)的分析和行为特征。
Drug Test Anal. 2020 Jun;12(6):812-826. doi: 10.1002/dta.2789. Epub 2020 Apr 20.
2
Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).麦角酰二乙酰胺的重现。第五部分:1-丁酰基-D-麦角酸二乙基酰胺(1B-LSD)的分析和行为特征。
Drug Test Anal. 2019 Aug;11(8):1122-1133. doi: 10.1002/dta.2613. Epub 2019 Jun 18.
3
Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).麦角酰胺类药物的回归。第一部分:1-丙酰基-d-麦角酸二乙酰胺(1P-LSD)的分析与行为特征
Drug Test Anal. 2016 Sep;8(9):891-902. doi: 10.1002/dta.1884. Epub 2015 Oct 12.
4
Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD).麦角酰二乙酰胺的重现。第七部分:1-戊酰基-d-麦角酸二乙基酰胺(1V-LSD)的分析和行为特征。
Drug Test Anal. 2022 Apr;14(4):733-740. doi: 10.1002/dta.3205. Epub 2021 Dec 8.
5
Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).1-酰基取代的二乙酰胺麦角酸(LSD)衍生物的药理学和生物转化研究。
Neuropharmacology. 2020 Aug 1;172:107856. doi: 10.1016/j.neuropharm.2019.107856. Epub 2019 Nov 19.
6
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).麦角酰胺类药物的回归。第四部分:麦角酸吗啉酯(LSM - 775)的分析与药理学特性
Drug Test Anal. 2018 Feb;10(2):310-322. doi: 10.1002/dta.2222. Epub 2017 Jul 27.
7
Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).LSD 类似物 N-乙基-N-环丙基麦角酰二乙胺(ECPLA)的药理学特征。
Psychopharmacology (Berl). 2019 Feb;236(2):799-808. doi: 10.1007/s00213-018-5055-9. Epub 2018 Oct 8.
8
Return of the lysergamides. Part II: Analytical and behavioural characterization of N -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).麦角酰胺类药物的回归。第二部分:N-烯丙基-6-去甲麦角酸二乙酰胺(AL-LAD)和(2'S,4'S)-麦角酸2,4-二甲基氮杂环丁酯(LSZ)的分析与行为特征
Drug Test Anal. 2017 Jan;9(1):38-50. doi: 10.1002/dta.1985. Epub 2016 Jun 6.
9
Return of the lysergamides. Part III: Analytical characterization of N -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD).麦角酰胺类药物的回归。第三部分:N-乙基-6-去甲麦角酸二乙酰胺(ETH-LAD)和1-丙酰基ETH-LAD(1P-ETH-LAD)的分析表征
Drug Test Anal. 2017 Oct;9(10):1641-1649. doi: 10.1002/dta.2196. Epub 2017 May 10.
10
Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.1P-AL-LAD 赖氨酰色胺的分析概况、体外代谢和行为特性。
Drug Test Anal. 2022 Aug;14(8):1503-1518. doi: 10.1002/dta.3281. Epub 2022 May 29.

引用本文的文献

1
Polydrug use during chemsex: single and intersecting sexual effects of commonly used drugs.性药滥用期间的多种药物使用:常用药物的单一及交叉性影响
Front Public Health. 2025 Jul 10;13:1618070. doi: 10.3389/fpubh.2025.1618070. eCollection 2025.
2
Evaluating the Potential of Microdosing 1cp-LSD for the Treatment of Canine Anxiety: A One-Month Case Study.评估微剂量1-环己基哌啶-LSD治疗犬类焦虑症的潜力:一项为期一个月的案例研究。
Vet Med Sci. 2025 Jul;11(4):e70486. doi: 10.1002/vms3.70486.
3
Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.

本文引用的文献

1
Identification of 1-Butyl-Lysergic Acid Diethylamide (1B-LSD) in Seized Blotter Paper Using an Integrated Workflow of Analytical Techniques and Chemo-Informatics.采用分析技术和 chemo-informatics 集成工作流程鉴定缴获的 blotter 纸上的 1-丁基-LSD(1B-LSD)。
Molecules. 2020 Feb 7;25(3):712. doi: 10.3390/molecules25030712.
2
Prodrugs of New Psychoactive Substances (NPS): A New Challenge.新精神活性物质(NPS)前药:新的挑战。
J Forensic Sci. 2020 May;65(3):913-920. doi: 10.1111/1556-4029.14268. Epub 2020 Jan 13.
3
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.
麦角酸二乙酰胺(LSD)在精神病学和神经科学中的临床研究。
Pharmaceuticals (Basel). 2025 Mar 29;18(4):499. doi: 10.3390/ph18040499.
4
Identification of two lysergic acid diethylamide analogs, 1-(3-(trimethylsilyl) propionyl) lysergic acid diethylamide (1S-LSD) and 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD), in paper sheet products distributed on the internet.在互联网上销售的纸片类产品中鉴定出两种麦角酸二乙酰胺类似物,即1-(3-(三甲基硅基)丙酰基)麦角酸二乙酰胺(1S-LSD)和1-(2-噻吩甲酰基)-6-烯丙基-去甲-d-麦角酸二乙酰胺(1T-AL-LAD)。
Forensic Toxicol. 2025 Apr 3. doi: 10.1007/s11419-025-00718-3.
5
Analytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD).1-(呋喃-2-羰基)-麦角酸二乙酰胺(1F-LSD)的分析与药理学特性及与1-(噻吩-2-羰基)-麦角酸二乙酰胺(1T-LSD)的比较
Drug Test Anal. 2024 Dec 3. doi: 10.1002/dta.3829.
6
Single-dose 1cp-LSD administration for canine anxiety: a pilot study.单剂量 1cp-LSD 给药治疗犬焦虑症:一项初步研究。
Vet Res Commun. 2024 Dec;48(6):4007-4014. doi: 10.1007/s11259-024-10542-6. Epub 2024 Sep 17.
7
Analytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD).1-己酰基-LSD(1H-LSD)的分析与行为特征
Drug Test Anal. 2025 Apr;17(4):561-569. doi: 10.1002/dta.3767. Epub 2024 Jul 4.
8
Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD).1-十二烷酰-LSD(1DD-LSD)的分析与行为特征
Drug Test Anal. 2025 Jan;17(1):101-109. doi: 10.1002/dta.3691. Epub 2024 Apr 3.
9
Identification of 1-(thiophene-2-carbonyl)-LSD from blotter paper falsely labeled "1D-LSD".从错误标记为“1D-LSD”的浸滤纸上鉴定出 1-(噻吩-2-羰基)-LSD。
Forensic Toxicol. 2024 Jan;42(1):93-101. doi: 10.1007/s11419-023-00668-8. Epub 2023 Jul 8.
10
Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products.鉴定片状产品中的 LSD 类似物,1cP-AL-LAD、1cP-MIPLA、1V-LSD 和 LSZ。
Forensic Toxicol. 2023 Jul;41(2):294-303. doi: 10.1007/s11419-023-00661-1. Epub 2023 Feb 21.
在小鼠头部震颤反应试验中致幻剂的效价与其他物种中的行为和主观效应之间的相关性。
Neuropharmacology. 2020 May 1;167:107933. doi: 10.1016/j.neuropharm.2019.107933. Epub 2020 Jan 7.
4
Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).1-酰基取代的二乙酰胺麦角酸(LSD)衍生物的药理学和生物转化研究。
Neuropharmacology. 2020 Aug 1;172:107856. doi: 10.1016/j.neuropharm.2019.107856. Epub 2019 Nov 19.
5
Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions.建立一种 LC-MS/MS 方法用于对尿液和血清中 1P-LSD 及其潜在代谢产物 LSD 进行定量分析,并对不同储存条件下 1P-LSD 的稳定性进行考察。
J Pharm Biomed Anal. 2019 Sep 10;174:270-276. doi: 10.1016/j.jpba.2019.05.062. Epub 2019 May 28.
6
Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).麦角酰二乙酰胺的重现。第五部分:1-丁酰基-D-麦角酸二乙基酰胺(1B-LSD)的分析和行为特征。
Drug Test Anal. 2019 Aug;11(8):1122-1133. doi: 10.1002/dta.2613. Epub 2019 Jun 18.
7
In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures.在体外 LSD 类新型精神活性物质的代谢命运及其在不同尿液筛查程序中的分析检测性。
Anal Bioanal Chem. 2019 Jul;411(19):4751-4763. doi: 10.1007/s00216-018-1558-9. Epub 2019 Jan 7.
8
Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).LSD 类似物 N-乙基-N-环丙基麦角酰二乙胺(ECPLA)的药理学特征。
Psychopharmacology (Berl). 2019 Feb;236(2):799-808. doi: 10.1007/s00213-018-5055-9. Epub 2018 Oct 8.
9
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).化学生物神经学中的黑暗经典:麦角酸二乙基酰胺(LSD)。
ACS Chem Neurosci. 2018 Oct 17;9(10):2331-2343. doi: 10.1021/acschemneuro.8b00043. Epub 2018 Mar 1.
10
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).麦角酰胺类药物的回归。第四部分:麦角酸吗啉酯(LSM - 775)的分析与药理学特性
Drug Test Anal. 2018 Feb;10(2):310-322. doi: 10.1002/dta.2222. Epub 2017 Jul 27.